financetom
Business
financetom
/
Business
/
Parex Q2 FFO hits $105 mln, net income $49 mln
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Parex Q2 FFO hits $105 mln, net income $49 mln
Jul 30, 2025 5:29 AM

Overview

* Parex Q2 2025 FFO reaches $105 mln, driven by operational efficiency

* Net income for Q2 2025 totals $49 mln, reflecting strong performance

* Company repurchased 630,000 shares and declared Q3 2025 dividend

Outlook

* Parex maintains FY 2025 production guidance at 43,000 to 47,000 boe/d

* Company expects incremental production growth from LLA-32, Capachos

* Parex benefits from favorable oil price differentials, reduced energy costs

* Company hedges Brent crude oil price risk for Q3 2025

Result Drivers

* OPERATIONAL EFFICIENCY - Strong Q2 results driven by operational efficiency and favorable crude oil price differentials, per CEO Imad Mohsen

* EXPLORATION SUCCESS - Successful near-field exploration wells contributing approximately 2,500 bbl/d to current production

* LOWER PRODUCTION EXPENSES - Reduced energy costs and efficiency initiatives lowering production expenses, slightly offset by higher current taxes

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Net $49 mln

Income

Q2 FFO $105 mln

Q2 FFO $1.08

Per

Share

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
NRX Pharmaceuticals Seeks FDA's Priority Review for Preservative-Free IV Ketamine
NRX Pharmaceuticals Seeks FDA's Priority Review for Preservative-Free IV Ketamine
Jun 5, 2025
08:40 AM EDT, 06/05/2025 (MT Newswires) -- NRX Pharmaceuticals ( NRXP ) said Thursday it is seeking priority review from the US Food and Drug Administration for its preservative-free intravenous ketamine formulation NRX-100 based on current and expected drug shortage. The company said it filed its abbreviated new drug application for NRX-100 for use in all existing approved indications, including...
Electra Battery Materials Completes Feasibility Level Study on Battery Recycling Facility
Electra Battery Materials Completes Feasibility Level Study on Battery Recycling Facility
Jun 5, 2025
08:39 AM EDT, 06/05/2025 (MT Newswires) -- Electra Battery Materials ( ELBM ) on Thursday announced the completion of a feasibility level Class 3 Engineering Study for the construction of a modular battery recycling facility adjacent to its cobalt sulfate refinery north of Toronto. A company statement noted that the facility will be designed to recover lithium, nickel, cobalt, manganese,...
WEC Energy to Offer $700 Million of Senior Notes Due 2028 Via Private Offering
WEC Energy to Offer $700 Million of Senior Notes Due 2028 Via Private Offering
Jun 5, 2025
08:39 AM EDT, 06/05/2025 (MT Newswires) -- WEC Energy Group ( WEC ) said Thursday it plans to offer $700 million in total principal amount of its convertible senior notes due 2028 via a private offering. The energy company said final terms of the notes will be determined at the time of pricing and that the notes will mature on...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved